BroTHaggS.Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. Eur J Ophthalmol. Epub ahead of print 23 October 2019. DOI: 10.1177/1120672119883602.
2.
CălugăruDCălugruM.Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.Can J Ophthalmol2017;
52(1): 137–138.
3.
CălugăruDCălugruM.Re: Bailey et al: intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the Ivan study. Ophthalmol2019;
126(9): e71–e72.
4.
CălugăruD and
Călugru M. Re: Li et al.: long-term assessment of macular atrophy in patients with age-related macular degeneration receiving anti-vascular endothelial growth factor.Ophthalmol Retina2018;
2(10): e13–e14.
5.
CălugăruDCălugruM.Conbercept for treatment of neovascular age-related macular degeneration: results of a randomized phase 3 Phoenix study. Am J Ophthalmol2019;
198: 262–263.
